Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life

Detalhes bibliográficos
Autor(a) principal: Mirochnick, Mark
Data de Publicação: 2011
Outros Autores: Nielsen-Saines, Karin, Pilotto, José Henrique, Pinto, Jorge, Veloso, Valdiléa G., Rossi, Steven, Moye, Jack, Bryson, Yvonne, Mofenson, Lynne, Camarca, Margaret, Watts, D. Heather
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/15868
Resumo: NICHD HPTN 040/PACTG 1043 Protocol team - We thank the patients and their families who enrolled in this trial. In addition to the authors, members of the NICHD/HPTN 040/PACTG 1043 protocol team include: Belo Horizonte- Federal University of Minas Gerais: Flavia Faleiro Ferreira, Fabiana Kakehasi. Hospital Geral de Nova Iguaçu: Jorge Eurico Ribeiro. Oswaldo Cruz Foundation, Rio de Janeiro (FIOCRUZ): Francisco Inacio Bastos, Beatriz Grinsztejn, Ronaldo Ismerio, Mariza Morgado, Marilia Santini de Oliveira, Valéria Ribeiro. Westat, Inc.: Emmanuel Aluko, Jim Bethel, Yolanda Bertucci, Patty Chen, Barbara Driver, Ruby Duston, Adriana Ferreira, Priya Guyadeen, Sarah Howell, Marsha Johnson, Naomi Leshabane, Lilya Meyerson, Rita Patel, Georgine Price, Susan Raitt, Eunice Yu. NICHD: Jennifer Read, George Siberry. Other protocol team members included Ruth Dickover from the University of CA-Davis, and Elizabeth Smith and Sheryl Zwerski from the National Institute of Allergy and Infectious Diseases, Diane Holland from the University of CA-San Diego Pediatric Pharmacology Laboratory. Pharmaceutical support and representatives included Marita McDonough from Boehringer-Ingelheim Pharmaceuticals, Inc. and Helen Watson from GlaxoSmithKline. This study was supported by NICHD Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001).
id CRUZ_cf4ba1e3c271e4242f348dd67a463dde
oai_identifier_str oai:www.arca.fiocruz.br:icict/15868
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Mirochnick, MarkNielsen-Saines, KarinPilotto, José HenriquePinto, JorgeVeloso, Valdiléa G.Rossi, StevenMoye, JackBryson, YvonneMofenson, LynneCamarca, MargaretWatts, D. Heather2016-09-20T14:58:54Z2016-09-20T14:58:54Z2011MIROCHNICK, Mark et al. Nelfinavir and Lamivudine Pharmacokinetics during the First Two Weeks of Life. The Pediatric Infectious Disease Journal, v. 30, n. 9, p. 769–772, Sept. 2011.0277-9730https://www.arca.fiocruz.br/handle/icict/1586810.1097/INF.0b013e31822429502331-3110NICHD HPTN 040/PACTG 1043 Protocol team - We thank the patients and their families who enrolled in this trial. In addition to the authors, members of the NICHD/HPTN 040/PACTG 1043 protocol team include: Belo Horizonte- Federal University of Minas Gerais: Flavia Faleiro Ferreira, Fabiana Kakehasi. Hospital Geral de Nova Iguaçu: Jorge Eurico Ribeiro. Oswaldo Cruz Foundation, Rio de Janeiro (FIOCRUZ): Francisco Inacio Bastos, Beatriz Grinsztejn, Ronaldo Ismerio, Mariza Morgado, Marilia Santini de Oliveira, Valéria Ribeiro. Westat, Inc.: Emmanuel Aluko, Jim Bethel, Yolanda Bertucci, Patty Chen, Barbara Driver, Ruby Duston, Adriana Ferreira, Priya Guyadeen, Sarah Howell, Marsha Johnson, Naomi Leshabane, Lilya Meyerson, Rita Patel, Georgine Price, Susan Raitt, Eunice Yu. NICHD: Jennifer Read, George Siberry. Other protocol team members included Ruth Dickover from the University of CA-Davis, and Elizabeth Smith and Sheryl Zwerski from the National Institute of Allergy and Infectious Diseases, Diane Holland from the University of CA-San Diego Pediatric Pharmacology Laboratory. Pharmaceutical support and representatives included Marita McDonough from Boehringer-Ingelheim Pharmaceuticals, Inc. and Helen Watson from GlaxoSmithKline. This study was supported by NICHD Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001).Sources of Funding: Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (contract NO1-HD33345), and co-sponsored by the HIV Prevention Trials Network (HPTN) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group.Boston University School of Medicine. Boston, MA, USA.University of California. David Geffen School of Medicine. Los Angeles, CA, USA.Hospital Geral de Nova Iguaçu. Nova Iguaçu, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.University of California. San Diego School of Medicine. Skaggs School of Pharmacy & Pharmaceutical Sciences. CA, USA.NIH. NICHD. DHHS. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.University of California. David Geffen School of Medicine. Los Angeles, CA, USA.NIH. NICHD. DHHS. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.Westat, Inc. Rockville, MD, USA.NIH. NICHD. DHHS. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.Background—There are no previous data describing nelfinavir and lamivudine pharmacokinetics in neonates treated with weight band dosing regimens. Design—Pharmacokinetic study of nelfinavir and lamivudine pharmacokinetics in infants during the first 2 weeks of life treated with weight band dosing regimens. Methods—Intensive 12 hour pharmacokinetic profiles were performed between either days 4–7 or days 10–14 of life in 26 Brazilian infants. Results—Pharmacokinetic data were obtained from 26 infants who received median (range) per kg doses of 58.8 (48.4–79.0) mg/kg for nelfinavir and 2.0 (1.5 – 3.2) mg/kg for lamivudine. Median nelfinavir AUC0-12 was 25.5 (1.7 – 183.5) μg*hr/mL and median C12h was 1.09 (<0.04 – 14.44) μg/mL. AUC0-12 was less than 15 μg*hr/mL (the 10% percentile for adults) in 12 infants (46%). Median lamivudine AUC0-12 was 7.8 (2.7–15.6) μg*hr/mL and median C12h was 0.23 (<0.04 – 0.74) μg/mL. Conclusions—Lamivudine pharmacokinetic parameters observed in this study were consistent with those seen in other studies of neonates. While median nelfinavir AUC and C12h in these neonates were above the exposure targets, interindividual variability in nelfinavir exposure was large and nelfinavir exposure failed to meet the exposure targets in 46% of infants.engdesconhecidoFarmacocinéticaRecém-NascidoNelfinavirLamivudinaNelfinavirLamivudinePharmacokineticsNewbornsNelfinavir and Lamivudine pharmacokinetics during the first two weeks of lifeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/15868/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALjose5_pilotto_etal_IOC_2011.pdfjose5_pilotto_etal_IOC_2011.pdfapplication/pdf318133https://www.arca.fiocruz.br/bitstream/icict/15868/2/jose5_pilotto_etal_IOC_2011.pdf3688733dc1e609eddb2d657ed9513dacMD52TEXTjose5_pilotto_etal_IOC_2011.pdf.txtjose5_pilotto_etal_IOC_2011.pdf.txtExtracted texttext/plain24956https://www.arca.fiocruz.br/bitstream/icict/15868/3/jose5_pilotto_etal_IOC_2011.pdf.txt71fab3d5c08204622f495b3d97e6128bMD53icict/158682023-03-30 22:09:16.947oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-31T01:09:16Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
title Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
spellingShingle Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
Mirochnick, Mark
Farmacocinética
Recém-Nascido
Nelfinavir
Lamivudina
Nelfinavir
Lamivudine
Pharmacokinetics
Newborns
title_short Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
title_full Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
title_fullStr Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
title_full_unstemmed Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
title_sort Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
author Mirochnick, Mark
author_facet Mirochnick, Mark
Nielsen-Saines, Karin
Pilotto, José Henrique
Pinto, Jorge
Veloso, Valdiléa G.
Rossi, Steven
Moye, Jack
Bryson, Yvonne
Mofenson, Lynne
Camarca, Margaret
Watts, D. Heather
author_role author
author2 Nielsen-Saines, Karin
Pilotto, José Henrique
Pinto, Jorge
Veloso, Valdiléa G.
Rossi, Steven
Moye, Jack
Bryson, Yvonne
Mofenson, Lynne
Camarca, Margaret
Watts, D. Heather
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Mirochnick, Mark
Nielsen-Saines, Karin
Pilotto, José Henrique
Pinto, Jorge
Veloso, Valdiléa G.
Rossi, Steven
Moye, Jack
Bryson, Yvonne
Mofenson, Lynne
Camarca, Margaret
Watts, D. Heather
dc.subject.other.pt_BR.fl_str_mv Farmacocinética
Recém-Nascido
Nelfinavir
Lamivudina
topic Farmacocinética
Recém-Nascido
Nelfinavir
Lamivudina
Nelfinavir
Lamivudine
Pharmacokinetics
Newborns
dc.subject.en.pt_BR.fl_str_mv Nelfinavir
Lamivudine
Pharmacokinetics
Newborns
description NICHD HPTN 040/PACTG 1043 Protocol team - We thank the patients and their families who enrolled in this trial. In addition to the authors, members of the NICHD/HPTN 040/PACTG 1043 protocol team include: Belo Horizonte- Federal University of Minas Gerais: Flavia Faleiro Ferreira, Fabiana Kakehasi. Hospital Geral de Nova Iguaçu: Jorge Eurico Ribeiro. Oswaldo Cruz Foundation, Rio de Janeiro (FIOCRUZ): Francisco Inacio Bastos, Beatriz Grinsztejn, Ronaldo Ismerio, Mariza Morgado, Marilia Santini de Oliveira, Valéria Ribeiro. Westat, Inc.: Emmanuel Aluko, Jim Bethel, Yolanda Bertucci, Patty Chen, Barbara Driver, Ruby Duston, Adriana Ferreira, Priya Guyadeen, Sarah Howell, Marsha Johnson, Naomi Leshabane, Lilya Meyerson, Rita Patel, Georgine Price, Susan Raitt, Eunice Yu. NICHD: Jennifer Read, George Siberry. Other protocol team members included Ruth Dickover from the University of CA-Davis, and Elizabeth Smith and Sheryl Zwerski from the National Institute of Allergy and Infectious Diseases, Diane Holland from the University of CA-San Diego Pediatric Pharmacology Laboratory. Pharmaceutical support and representatives included Marita McDonough from Boehringer-Ingelheim Pharmaceuticals, Inc. and Helen Watson from GlaxoSmithKline. This study was supported by NICHD Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001).
publishDate 2011
dc.date.issued.fl_str_mv 2011
dc.date.accessioned.fl_str_mv 2016-09-20T14:58:54Z
dc.date.available.fl_str_mv 2016-09-20T14:58:54Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MIROCHNICK, Mark et al. Nelfinavir and Lamivudine Pharmacokinetics during the First Two Weeks of Life. The Pediatric Infectious Disease Journal, v. 30, n. 9, p. 769–772, Sept. 2011.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/15868
dc.identifier.issn.pt_BR.fl_str_mv 0277-9730
dc.identifier.doi.none.fl_str_mv 10.1097/INF.0b013e3182242950
dc.identifier.eissn.none.fl_str_mv 2331-3110
identifier_str_mv MIROCHNICK, Mark et al. Nelfinavir and Lamivudine Pharmacokinetics during the First Two Weeks of Life. The Pediatric Infectious Disease Journal, v. 30, n. 9, p. 769–772, Sept. 2011.
0277-9730
10.1097/INF.0b013e3182242950
2331-3110
url https://www.arca.fiocruz.br/handle/icict/15868
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv desconhecido
publisher.none.fl_str_mv desconhecido
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/15868/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/15868/2/jose5_pilotto_etal_IOC_2011.pdf
https://www.arca.fiocruz.br/bitstream/icict/15868/3/jose5_pilotto_etal_IOC_2011.pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
3688733dc1e609eddb2d657ed9513dac
71fab3d5c08204622f495b3d97e6128b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324901288869888

Registros relacionados